Pacylex Pharmaceuticals
Latest round
- Series A
Last raised
- Jun 2021
Total raised
- Undisclosed
Investors
- 1
About Pacylex Pharmaceuticals
Pacylex Pharmaceuticals, Inc., founded in 2012 in Edmonton, Canada, specializes in oncology therapeutics.90 mn.Pacylex Pharmaceuticals Inc. focuses on developing innovative cancer therapies, primarily centered around its lead product, zelenirstat, which is a first-in-class oral myristoylation inhibitor. This therapy targets N-myristoyltransferase (NMT) to disrupt myristoylation, a process essential for numerous cancer cell functions, thereby providing a new treatment option for patients with refractory cancers. Zelenirstat is designed for daily oral administration, boasting features such as excellent bioavailability and a favorable safety profile, making it suitable for various solid tumors and hematological malignancies. The company's development efforts are particularly aimed at addressing urgent needs in oncology, specifically targeting leukemias, lymphomas, and other cancers where traditional treatments have limited efficacy.While specific revenue figures for Pacylex Pharmaceuticals are not disclosed, the company's business model revolves around partnerships and collaborations for the development and commercialization of its therapeutic offerings. Revenue generation may occur through arrangements with pharmaceutical companies and research institutions focused on oncology, where Pacylex provides its innovative drug formulations for clinical trials or licensing agreements. The flagship product, zelenirstat, is positioned within a framework that involves various transaction structures such as B2B partnerships for drug development, alongside direct collaborations for potential market access. Given its focus on oncology, Pacylex's clientele primarily includes healthcare providers, oncology specialists, and research institutions.90 mn to support the initial Phase 1 clinical investigation of PCLX-001, an N-myristoyl transferase inhibitor aimed at treating solid tumors and lymphoma patients. The company is actively working on expanding its therapeutic portfolio and intends to explore new markets, particularly within North America and beyond, by deploying strategies aimed at enhancing its product development pipeline.
Who invested in Pacylex Pharmaceuticals
1 investor across 1 round
See all investors in Pacylex Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 2, 2021
Amount
Undisclosed
Investors
Questions about Pacylex Pharmaceuticals
Who invested in Pacylex Pharmaceuticals?
Pacylex Pharmaceuticals has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pacylex Pharmaceuticals raised?
Pacylex Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Pacylex Pharmaceuticals last raise money?
Pacylex Pharmaceuticals's most recent round on record is a Series A, in Jun 2021.
What does Pacylex Pharmaceuticals do?
Pacylex Pharmaceuticals is a pharmaceuticals company.
Where is Pacylex Pharmaceuticals headquartered?
Pacylex Pharmaceuticals is headquartered in Edmonton, Canada.
Which VCs invest in companies like Pacylex Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Pacylex Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Pacylex Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.